Search

Search Constraints

You searched for: Author/Creator Jodrell, D.

Search Results

2. Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours. Issue 2 (January 2015)